{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:08:27Z","timestamp":1788786507182,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Urothelial carcinoma, the second most common urological malignancy, can arise in both the lower and upper urinary tract, with approximately 90\u201395% arising in the bladder, while urothelial carcinomas of the upper urinary tract account for only 5\u201310%. Treatment options depend on many factors, such as grade and risk factors, but include surgery, chemotherapy, and immunotherapy. Due to the unique pathological and molecular characteristics of each patient, some therapies are ineffective, and the need for targeted therapies and precision medicine is growing. The interactions of malignant cells within the tumor microenvironment can be decisive for the course of therapy. These interactions include components of the complement system, which is a highly conserved part of the innate immune system. The role of the complement system, especially the anaphylatoxin receptors C5aR1 and C5aR2, in cancer is complex. C5aR1 appears to be tumor-promoting by inhibiting the T cell response and modulating the TME, while C5aR2 plays an ambivalent role and was shown to counteract tumor development in some mouse models while in other types of cancer it stimulated tumor growth and led to chemoresistance. In urothelial carcinomas, C5aR1 has been described as a prognostic factor, while C5aR2 has not been considered to date. Here, we briefly summarize our current knowledge of the complex functions of C5a receptors in cancer. In particular, this is the first focused summary of data on C5a receptors in urothelial carcinomas.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1885439","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:17:05Z","timestamp":1788783425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas"],"prefix":"10.3389","volume":"17","author":[{"given":"Lea Sophie","family":"L\u00fctje","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital Schleswig-Holstein Campus L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gruner","sequence":"additional","affiliation":[{"name":"Institute for Systemic Inflammation Research, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Marcel","family":"Karsten","sequence":"additional","affiliation":[{"name":"Institute for Systemic Inflammation Research, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Stuart","family":"Merseburger","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Schleswig-Holstein Campus L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Roesch","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Schleswig-Holstein Campus L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J Clin"},{"key":"B2","article-title":"EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS)","volume-title":"EAU Guidelines on non-Muscle-Invasive Bladder Cancer (T1, T1 and CIS)","author":"Gontero","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comp\u00e9rat","year":"2015","journal-title":"Virchows Arch"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0594-7","article-title":"Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma","volume":"29","author":"Shariat","year":"2011","journal-title":"World J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2350820","DOI":"10.1002\/eji.202350820","article-title":"The complement system as a target in cancer immunotherapy","volume":"54","author":"Merle","year":"2024","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04633.x","article-title":"Clinical significance of complement deficiencies","volume":"1173","author":"Pettigrew","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15503","article-title":"Canonical and non\u2010canonical functions of the complement system in health and disease","volume":"178","author":"Wenzel","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B13","first-page":"1","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume-title":"Advances in Clinical Chemistry","author":"Frazer-Abel","year":"2016"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: History, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Medi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311261110","article-title":"Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3","volume":"110","author":"Bajic","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.2953","article-title":"Comparative functional evolution of human and mouse CR1 and CR2","volume":"181","author":"Jacobson","year":"2008","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1016\/j.cell.2023.09.020","article-title":"Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors","volume":"186","author":"Yadav","year":"2023","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03260-6","article-title":"Complement system in tumor growth and metastases","volume":"134","author":"Borisov","year":"2026","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12935-019-1027-3","article-title":"Role of the complement system in the tumor microenvironment","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.03.009","article-title":"Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response","volume":"42","author":"Surace","year":"2015","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-323-87763-3.00012-5","article-title":"The role of the complement system in cancer etiology and management","volume-title":"Clinical Immuno-Oncology","author":"Sonderegger","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.12.010","article-title":"Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity","volume":"32","author":"Luan","year":"2024","journal-title":"Mol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/biology14111491","article-title":"Targeting C3a and C5a signaling\u2014A game changer for cancer therapy","volume":"14","author":"Hudgins","year":"2025","journal-title":"Biology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0157","article-title":"Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche","volume":"74","author":"Vadrevu","year":"2014","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013290","article-title":"Complement system in cancer: Friend or foe of immunotherapy","volume":"14","author":"Shah","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101951","article-title":"Interplay between the complement system and other immune pathways in the tumor microenvironment","volume":"78","author":"Garlanda","year":"2025","journal-title":"Semin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122311","article-title":"Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment","volume":"4","author":"Singel","year":"2019","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/2326-6066.CIR-20-0922","article-title":"Mechanisms driving neutrophil-induced T-cell immunoparalysis in ovarian cancer","volume":"9","author":"Emmons","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","article-title":"A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis","volume":"7","author":"Ajona","year":"2017","journal-title":"Cancer Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.612622","article-title":"Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration","volume":"290","author":"Piao","year":"2015","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010022","article-title":"Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells","volume":"18","author":"Han","year":"2017","journal-title":"IJMS"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201800980RR","article-title":"C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma","volume":"33","author":"Nabizadeh","year":"2019","journal-title":"FASEB J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2021.12.027","article-title":"Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis","volume":"529","author":"Ortiz-Espinosa","year":"2022","journal-title":"Cancer Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736725","article-title":"An integrated analysis of C5AR2 related to Malignant properties and immune infiltration of breast cancer","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45058","article-title":"C5aR1 is a master regulator in colorectal tumorigenesis via immune modulation","volume":"10","author":"Ding","year":"2020","journal-title":"Theranostics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jid.2020.06.025","article-title":"C3 drives inflammatory skin carcinogenesis independently of C5","volume":"141","author":"Jackson","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.29","article-title":"An integrated analysis of C5AR2 related to Malignant properties and immune infiltration of gliomas","volume":"1","author":"Huang","year":"2022","journal-title":"Cancer Innovation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7150\/jca.15339","article-title":"Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder","volume":"7","author":"Chang","year":"2016","journal-title":"J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1985.tb01673.x","article-title":"A human cell\u2010surface antigen defined by a monoclonal antibody and controlled by a gene on human chromosome 1","volume":"49","author":"Andrews","year":"1985","journal-title":"Ann Hum Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.09.016","article-title":"CD46: The \u2018multitasker\u2019 of complement proteins","volume":"45","author":"Yamamoto","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3892\/ijo.2024.5659","article-title":"Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9","volume":"65","author":"Thi","year":"2024","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040735","article-title":"Proteomic and in silico analyses highlight complement system\u2019s role in bladder cancer immune regulation","volume":"61","author":"Korak","year":"2025","journal-title":"Medicina"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.3892\/ol.2016.5137","article-title":"C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy","volume":"12","author":"Wada","year":"2016","journal-title":"Oncol Lett"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1186\/s12885-021-08883-5","article-title":"Clinicopathological features and prognostic significance of C5aR in human solid tumors: A meta-analysis","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164124","article-title":"Pan-cancer analysis of immune complement signature C3\/C5\/C3AR1\/C5AR1 in association with tumor immune evasion and therapy resistance","volume":"13","author":"Lawal","year":"2021","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","article-title":"Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy","volume":"34","author":"Medler","year":"2018","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34474","article-title":"Complement receptor C5aR1 blockade reprograms tumor\u2010associated macrophages and synergizes with anti\u2010PD \u20101 therapy in gastric cancer","volume":"153","author":"Zhang","year":"2023","journal-title":"Intl J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2261242","article-title":"C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"OncoImmunology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"v492","DOI":"10.1093\/annonc\/mdz253.029","article-title":"Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours","volume":"30","author":"Massard","year":"2019","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.annonc.2022.01.023","article-title":"15P STELLAR-001: A phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors","volume":"33","author":"Bennouna","year":"2022","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101921","article-title":"The complement system in clinical oncology: Applications, limitations and challenges","volume":"77","author":"Ajona","year":"2025","journal-title":"Semin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-258","article-title":"Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer","volume":"12","author":"Yuan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168277","article-title":"Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1","volume":"133","author":"Beach","year":"2023","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.01.004","article-title":"The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis","volume":"39","author":"Packiam","year":"2021","journal-title":"Urologic Oncol Semin Original Investigations"},{"key":"B61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cpt.2023.11.004","article-title":"Theories behind Bacillus Calmette-Gu\u00e9rin failure in high-risk non-muscle-invasive bladder cancer and update on current management","volume":"2","author":"Maroof","year":"2024","journal-title":"Cancer Pathogenesis Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/CMAR.S418009","article-title":"Current and emerging treatments for urothelial carcinoma: A focus on Enfortumab Vedotin","volume":"15","author":"Shafique","year":"2023","journal-title":"CMAR"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.03.010","article-title":"Acquired resistance to immunotherapy in solid tumors","volume":"31","author":"Verdys","year":"2025","journal-title":"Trends Mol Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"JCO"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/jpm16010025","article-title":"Emerging molecular and computational biomarkers in urothelial carcinoma: Innovations in diagnosis, prognosis, and therapeutic response prediction","volume":"16","author":"Alberca-del Arco","year":"2026","journal-title":"JPM"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:17:07Z","timestamp":1788783427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2026.1885439"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1885439","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1885439"}}